4h
Hosted on MSNEli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...
The weakness was also weighing on shares of some of Walmart's rivals, as Costco Wholesale Corp.'s stock (COST) fell 2.2% and Target Corp. shares (TGT) shed 1.1%, to underperform the S&P 500 index's ...
Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 6.29% gross of fees, underperforming the 7.07% ...
But these nitpickers miss the big picture. Splits matter - because these stocks outperform after the announcement, by a lot. Average returns one year later are 25% vs. 12% for the S&P 500 SPX as a ...
Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...
The Fund lagged the benchmark composite index, which was up 15.01%, while the Fund underperformed the Morningstar Moderate ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results